bluebird bio to split into oncology and gene therapy specialists
pharmaphorum
JANUARY 11, 2021
million price tag. On the oncology side, bluebird has also strengthened its board with the appointment of Dr Ramy Ibrahim, a high-profile leader in clinical development in immunotherapy and cell therapy. Zynteglo is already in beta-thalassemia in Europe, where the company will seek to expand access despite its hefty $1.8
Let's personalize your content